DOI:
10.1055/s-00000004
Aktuelle Neurologie
LinksClose Window
References
Bielekova B, Catalfamo M, Reichert-Scrivner S. et al.
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Proc Natl Acad Sci U S A 2006;
103: 5941-5946
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.